Wednesday, April 2, 2025 (Healthday News)-The Telehealth Company Hims & Hers Herhth is expanding its Weight-Offings by Adding New Medications to its Platform.
The Company Said Tuesday it now Provides Access to Zepbound, the Brand-Name Version of the Drug tirzepatideas wells to generic liraglutide.
Zepbound is Made by Drugmaker Eli Lilly. While Hims & Hers Offers It for $ 1,899 Per Month, Lilly Said the Price on Its Own Lillydirect Platform Starts at $ 349 for Self-Paying Customers. With insurance, disappear may pay the os lytle as $ 25, according to report published by The Wall Street Journal.
Other Medications for Weight Loss on the Hims & Hers Platform Include Ozempic and WegovyPriced at $ 1,799 and $ 1,999 per month, respectively.
“We’ve Now Expanded that Choice Even Further by Adding Access to Generic Liraglutide and Branded Tirzepatide Through Our Platform,” Hims & Hers Said.
Lilly Said it has in the official Connection with Hims & Hers.
Hims & Hers Said it Plans to Keep Expanding its Offerings To Help People Find the Treatment That Works Best for Them.
“All of this is part of our long-term commitment to build the most comprehensive and personalized digital health platform for weight loss and beyond,” Hims & Hers Noted.
The Company’s Weights Business Is Growing Fast. Hims & Hers Expects at Least $ 725 Million In Revenue from its Weight-me Services Alone in 2025.
In 2023, The Company Brought in Nearly $ 1.5 Billion from More Than 2 Million Customers.
In the Fourth Quarter of 2023, The Company Launched An Oral Weight-Less Program, Reaching $ 100 Million In Revenue in Just Seven Months.
It added GLP-1 Drugs Like Tirzepatide in Mid-2024, Which Brought in About $ 225 Million More That Year.
In February, CEO Andrew Dudum Said 200,000 New Customers Joined the Platform for Weights Help Over the Past Year.
Chief Financial Officer Yemi Okupe ADDED, “Consumes are very motivated to lose weight and have a Holistic Platform to Do So.”
More information
The Obesity Medicine Association Has More on the Top Weight Loss Medications.
Source: The Wall Street JournalApril 1, 2025
Copyright © 2025 Healthday. All Rights Reserved.
